Brief: Cingulate Completes CTx-2103 Human Formulation Study For Anxiety Disorders Treatment
23/06/2022 12:12
June 23 (Reuters) - Cingulate Inc CING.O :
* CINGULATE ANNOUNCES COMPLETION OF CTX-2103 HUMAN
FORMULATION
STUDY FOR THE TREATMENT OF ANXIETY DISORDERS
* CINGULATE INC - STUDY WAS CONDUCTED AT BDD PHARMA IN
UNITED
KINGDOM. RESULTS ARE EXPECTED IN AUGUST 2022
Source text for Eikon: ID:nGNX2VSrVj
Further company coverage: CING.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)